Sunday, February 8 2026
1:55–2:40pm
CME/CE
Chronic Kidney Disease, Guidelines, and Newer Medications
Description
The medical management of Chronic Kidney Disease (CKD) has become an integral responsibility of Primary care physicians. The KDIGO guidelines on the long-term care of CKD patients were published in 2024 and will be reviewed in detail with attention to the availability of new pharmacotherapy for nephroprotection. A stepwise approach to slowing the progression of CKD will be presented. An open Q&A session will follow the presentation
Learning Objectives
- Review the diagnosis and long-term complications of CKD
- Discuss the concept of Nephroprotection and the physiologic principles that play a role in progressive kidney disease
- Review the role of RAAS inhibitors, SGLT2 inhibitors, Mineralocorticoid inhibitors and GLP-1 agonists in slowing the progression of CKD
- Define the important role of potassium binders in achieving maximal nephroprotection